Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

A team from the Institute of Cancer Research, London, found NXP800 slowed the growth of prostate cancer cells, including ...

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with an alcohol) to be locked treasure chests of possibilities.

Opioid misuse and specifically opioid use disorder (OUD), continues to represent a significant U.S. public health threat, with more than 6 million Americans aged 12 and older meeting the criteria for ...

New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...

The flourishing gray market for intoxicating hemp products like Delta-8 is harming the legal cannabis market while ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies.